Top

Published in:

Open Access 01-12-2018 | Research

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA

Authors: Simon Heine, Markus Kleih, Neus Giménez, Kathrin Böpple, German Ott, Dolors Colomer, Walter E. Aulitzky, Heiko van der Kuip, Elisabeth Silkenstedt

Published in: Journal of Hematology & Oncology | Issue 1/2018

Abstract

Background

Mantle cell lymphoma (MCL) is an aggressive B-non-Hodgkin lymphoma with generally poor outcome. MCL is characterized by an aberrantly high cyclin D1-driven CDK4 activity. New molecular targeted therapies such as inhibitors of the ubiquitin-proteasome system (UPS) have shown promising results in preclinical studies and MCL patients. Our previous research revealed stabilization of the short-lived pro-apoptotic NOXA as a critical determinant for sensitivity to these inhibitors. It is currently unclear how cyclin D1 overexpression and aberrant CDK4 activity affect NOXA stabilization and treatment efficacy of UPS inhibitors in MCL.

Methods

The effect of cyclin D1-driven CDK4 activity on response of MCL cell lines and primary cells to proteasome inhibitor treatment was investigated using survival assays (Flow cytometry, AnnexinV/PI) and Western blot analysis of NOXA protein. Half-life of NOXA protein was determined by cycloheximide treatment and subsequent Western blot analysis. The role of autophagy was analyzed by LC3-II protein expression and autophagolysosome detection. Furthermore, silencing of autophagy-related genes was performed using siRNA and MCL cells were treated with autophagy inhibitors in combination with proteasome and CDK4 inhibition.

Results

In this study, we show that proteasome inhibitor-mediated cell death in MCL depends on cyclin D1-driven CDK4 activity. Inhibition of cyclin D1/CDK4 activity significantly reduced proteasome inhibitor-mediated stabilization of NOXA protein, mainly driven by an autophagy-mediated proteolysis. Bortezomib-induced cell death was significantly potentiated by compounds that interfere with autophagosomal function. Combined treatment with bortezomib and autophagy inhibitors enhanced NOXA stability leading to super-induction of NOXA protein. In addition to established autophagy modulators, we identified the fatty acid synthase inhibitor orlistat to be an efficient autophagy inhibitor when used in combination with bortezomib. Accordingly, this combination synergistically induced apoptosis both in MCL cell lines and in patient samples.

Conclusion

Our data demonstrate that CDK4 activity in MCL is critical for NOXA stabilization upon treatment with UPS inhibitors allowing preferential induction of cell death in cyclin D transformed cells. Under UPS blocked conditions, autophagy appears as the critical regulator of NOXA induction. Therefore, inhibitors of autophagy are promising candidates to increase the activity of proteasome inhibitors in MCL.

Available only for authorised users

Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–71. https://doi.org/10.1093/annonc/mdx223.CrossRefPubMed

Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416–23. https://doi.org/10.1172/JCI61272.CrossRefPubMedPubMedCentral

Fernàndez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol. 2005;23:6364–9. https://doi.org/10.1200/JCO.2005.05.019.CrossRefPubMed

Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551–5.CrossRefPubMed

Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. 2006;108:1744–50. https://doi.org/10.1182/blood-2006-04-016634.CrossRefPubMedPubMedCentral

Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med. 2016;94:1313–26. https://doi.org/10.1007/s00109-016-1475-3.CrossRefPubMedPubMedCentral

Valenzuela CA, Vargas L, Martinez V, Bravo S, Brown NE. Palbociclib-induced autophagy and senescence in gastric cancer cells. Exp Cell Res. 2017;360:390–6. https://doi.org/10.1016/j.yexcr.2017.09.031.CrossRefPubMed

Acevedo M, Vernier M, Mignacca L, Lessard F, Huot G, Moiseeva O, et al. A CDK4/6-dependent epigenetic mechanism protects cancer cells from PML-induced senescence. Cancer Res. 2016;76:3252–64. https://doi.org/10.1158/0008-5472.CAN-15-2347.CrossRefPubMed

Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, et al. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017;8:15916. https://doi.org/10.1038/ncomms15916.CrossRefPubMedPubMedCentral

10.

Brown NE, Jeselsohn R, Bihani T, Hu MG, Foltopoulou P, Kuperwasser C, Hinds PW. Cyclin D1 activity regulates autophagy and senescence in the mammary epithelium. Cancer Res. 2012;72:6477–89. https://doi.org/10.1158/0008-5472.CAN-11-4139.CrossRefPubMedPubMedCentral

11.

Okada Y, Kato S, Sakamoto Y, Oishi T, Ishioka C. Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines. Oncol Rep. 2017;38:31–42. https://doi.org/10.3892/or.2017.5684.CrossRefPubMedPubMedCentral

12.

Doorduijn JK, Minnema MC, Kersten MJ, Lugtenburg PJ, Schipperus MR, van Marwijk Kooy M, et al. Bortezomib maintenance therapy after induction with R-CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicenter phase II HOVON study. Blood. 2015;23:339.

13.

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–53. https://doi.org/10.1056/NEJMoa1412096.CrossRefPubMed

14.

Smith AJ, Dai H, Correia C, Takahashi R, Lee S-H, Schmitz I, Kaufmann SH. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem. 2011;286:17682–92. https://doi.org/10.1074/jbc.M110.189092.CrossRefPubMedPubMedCentral

15.

Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489–99. https://doi.org/10.1182/blood-2007-08-104950.CrossRefPubMed

16.

Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti EG, Chapman CM, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood. 2011;117:542–52. https://doi.org/10.1182/blood-2010-02-269514.CrossRefPubMedPubMedCentral

17.

Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer. 2008;7:40. https://doi.org/10.1186/1476-4598-7-40.CrossRefPubMedPubMedCentral

18.

Chen Z, Teo AE, McCarty N. ROS-induced CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival and drug resistance in the bone marrow microenvironment via autophagy. Clin Cancer Res. 2016;22:187–99. https://doi.org/10.1158/1078-0432.CCR-15-0987.CrossRefPubMed

19.

Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol. 2008;80:133–42. https://doi.org/10.1111/j.1600-0609.2007.00995.x. CrossRefPubMed

20.

Roué G, Pérez-Galán P, Mozos A, López-Guerra M, Xargay-Torrent S, Rosich L, et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood. 2011;117:1270–9. https://doi.org/10.1182/blood-2010-04-278853.CrossRefPubMed

21.

Qu F-L, Xia B, Li S-X, Tian C, Yang H-L, Li Q, et al. Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth. Cancer Biol Med. 2015;12:401–8. https://doi.org/10.7497/j.issn.2095-3941.2015.0013.PubMedPubMedCentralCrossRef

22.

Zhao L-L, Liu Y-F, Peng L-J, Fei A-M, Cui W, Miao S-C, et al. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib. Cancer Med. 2015;4:1754–66. https://doi.org/10.1002/cam4.511.CrossRefPubMedPubMedCentral

23.

Leshchenko VV, Kuo P-Y, Jiang Z, Weniger MA, Overbey J, Dunleavy K, et al. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. Oncotarget. 2015;6:27332–42. https://doi.org/10.18632/oncotarget.2903.CrossRefPubMedPubMedCentral

24.

Dengler MA, Weilbacher A, Gutekunst M, Staiger AM, Vöhringer MC, Horn H, et al. Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles’ heel in mantle cell lymphoma. Cell Death Dis. 2014;5:e1013. https://doi.org/10.1038/cddis.2013.552.CrossRefPubMedPubMedCentral

25.

Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27–55. https://doi.org/10.1016/0065-2571(84)90007-4.CrossRef

26.

Haubeiss S, Schmid JO, Mürdter TE, Sonnenberg M, Friedel G, van der Kuip H, Aulitzky WE. Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010;9:168. https://doi.org/10.1186/1476-4598-9-168.CrossRefPubMedPubMedCentral

27.

Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 2011;17:5101–12. https://doi.org/10.1158/1078-0432.CCR-10-3367.CrossRefPubMedPubMedCentral

28.

Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257–64. https://doi.org/10.1182/blood-2005-05-2091.CrossRefPubMed

29.

Bustany S, Cahu J, Guardiola P, Sola B. Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway. BMC Cancer. 2015;15:262. https://doi.org/10.1186/s12885-015-1240-y.CrossRefPubMedPubMedCentral

30.

Medina DJ, Goodell L, Glod J, Gélinas C, Rabson AB, Strair RK. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways. Haematologica. 2012;97:1255–63. https://doi.org/10.3324/haematol.2011.040659.CrossRefPubMedPubMedCentral

31.

Chiron D, Dousset C, Brosseau C, Touzeau C, Maïga S, Moreau P, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6:8750–9. https://doi.org/10.18632/oncotarget.3275.CrossRefPubMedPubMedCentral

32.

Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383–91. https://doi.org/10.1158/0008-5472.CAN-06-4086.CrossRefPubMed

33.

Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17:2734–43. https://doi.org/10.1158/1078-0432.CCR-10-1950.CrossRefPubMed

34.

Aikawa T, Shinzawa K, Tanaka N, Tsujimoto Y. Noxa is necessary for hydrogen peroxide-induced caspase-dependent cell death. FEBS Lett. 2010;584:681–8. https://doi.org/10.1016/j.febslet.2010.01.026.CrossRefPubMed

35.

Qin J-Z, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65:6282–93. https://doi.org/10.1158/0008-5472.CAN-05-0676.CrossRefPubMed

36.

Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, et al. Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep. 2013;3:881–91. https://doi.org/10.1016/j.celrep.2013.02.014.CrossRefPubMed

37.

Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R, et al. Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica. 2010;95:1510–8. https://doi.org/10.3324/haematol.2010.022368.CrossRefPubMedPubMedCentral

38.

Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms. Autophagy. 2017:1–9. https://doi.org/10.1080/15548627.2017.1378838.

39.

Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1–222. https://doi.org/10.1080/15548627.2015.1100356. CrossRefPubMedPubMedCentral

40.

Amaravadi RK, Lippincott-Schwartz J, Yin X-M, Weiss WA, Takebe N, Timmer W, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17:654–66. https://doi.org/10.1158/1078-0432.CCR-10-2634.CrossRefPubMedPubMedCentral

41.

Höring E, Montraveta A, Heine S, Kleih M, Schaaf L, Vöhringer MC, et al. Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. Br J Haematol. 2017;177:557–61. https://doi.org/10.1111/bjh.14571.CrossRefPubMed

42.

Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64:2070–5. https://doi.org/10.1158/0008-5472.CAN-03-3645.CrossRefPubMed

43.

Liu J, Chang F, Li F, Fu H, Wang J, Zhang S, et al. Palmitate promotes autophagy and apoptosis through ROS-dependent JNK and p38 MAPK. Biochem Biophys Res Commun. 2015;463:262–7. https://doi.org/10.1016/j.bbrc.2015.05.042.CrossRefPubMed

44.

Chen Y-Y, Sun L-Q, Wang B-A, Zou X-M, Mu Y-M, Lu J-M. Palmitate induces autophagy in pancreatic β-cells via endoplasmic reticulum stress and its downstream JNK pathway. Int J Mol Med. 2013;32:1401–6. https://doi.org/10.3892/ijmm.2013.1530.CrossRefPubMed

45.

Park M, Sabetski A, Kwan Chan Y, Turdi S, Sweeney G. Palmitate induces ER stress and autophagy in H9c2 cells: implications for apoptosis and adiponectin resistance. J Cell Physiol. 2015;230:630–9. https://doi.org/10.1002/jcp.24781.CrossRefPubMed

46.

Komatsu M, Ichimura Y. Physiological significance of selective degradation of p62 by autophagy. FEBS Lett. 2010;584:1374–8. https://doi.org/10.1016/j.febslet.2010.02.017.CrossRefPubMed

47.

Specht K, Haralambieva E, Bink K, Kremer M, Mandl-Weber S, Koch I, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood. 2004;104:1120–6. https://doi.org/10.1182/blood-2003-11-3837.CrossRefPubMed

48.

Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101–19. https://doi.org/10.1016/j.mayocp.2015.11.007.CrossRefPubMedPubMedCentral

49.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 2007;67:5418–24. https://doi.org/10.1158/0008-5472.CAN-06-4322.CrossRefPubMed

50.

Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst. 2006;98:1238–47. https://doi.org/10.1093/jnci/djj334.CrossRefPubMed

51.

Hsieh F-S, Chen Y-L, Hung M-H, Chu P-Y, Tsai M-H, Chen L-J, et al. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner. Mol Oncol. 2017;11:1035–49. https://doi.org/10.1002/1878-0261.12072.CrossRefPubMedPubMedCentral

52.

Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132–41. https://doi.org/10.1038/ncb2152.CrossRefPubMedPubMedCentral

53.

Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia. 2009;23:784–90. https://doi.org/10.1038/leu.2008.348.CrossRefPubMed

54.

Rosich L, Xargay-Torrent S, López-Guerra M, Campo E, Colomer D, Roué G. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clin Cancer Res. 2012;18:5278–89. https://doi.org/10.1158/1078-0432.CCR-12-0351.CrossRefPubMed

55.

Liu WJ, Ye L, Huang WF, Guo LJ, Xu ZG, Wu HL, et al. p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell Mol Biol Lett. 2016;21:29. https://doi.org/10.1186/s11658-016-0031-z.CrossRefPubMedPubMedCentral

56.

Craxton A, Butterworth M, Harper N, Fairall L, Schwabe J, Ciechanover A, Cohen GM. NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1. Cell Death Differ. 2012;19:1424–34. https://doi.org/10.1038/cdd.2012.16.CrossRefPubMedPubMedCentral

57.

Ji CH, Kwon YT. Crosstalk and interplay between the ubiquitin-proteasome system and autophagy. Mol Cells. 2017;40:441–9. https://doi.org/10.14348/molcells.2017.0115.PubMedPubMedCentralCrossRef

58.

Kaushik S, Bandyopadhyay U, Sridhar S, Kiffin R, Martinez-Vicente M, Kon M, et al. Chaperone-mediated autophagy at a glance. J Cell Sci. 2011;124:495–9. https://doi.org/10.1242/jcs.073874.CrossRefPubMedPubMedCentral

59.

D-w W, Z-j P, G-f R, G-x W. The different roles of selective autophagic protein degradation in mammalian cells. Oncotarget. 2015;6:37098–116. https://doi.org/10.18632/oncotarget.5776.CrossRef

60.

Morgan MJ, Gamez G, Menke C, Hernandez A, Thorburn J, Gidan F, et al. Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent. Autophagy. 2014;10:1814–26. https://doi.org/10.4161/auto.32135.CrossRefPubMedPubMedCentral

61.

Vogl DT, Stadtmauer EA, Tan K-S, Heitjan DF, Davis LE, Pontiggia L, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014;10:1380–90. https://doi.org/10.4161/auto.29264.CrossRefPubMedPubMedCentral

62.

Chude CI, Amaravadi RK. Targeting autophagy in cancer: update on clinical trials and novel inhibitors. Int J Mol Sci. 2017; https://doi.org/10.3390/ijms18061279.

63.

Yoshida GJ. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol. 2017;10:67. https://doi.org/10.1186/s13045-017-0436-9.CrossRefPubMedPubMedCentral

64.

Velázquez AP, Tatsuta T, Ghillebert R, Drescher I, Graef M. Lipid droplet-mediated ER homeostasis regulates autophagy and cell survival during starvation. J Cell Biol. 2016;212:621–31. https://doi.org/10.1083/jcb.201508102.CrossRefPubMedPubMedCentral

65.

Shpilka T, Welter E, Borovsky N, Amar N, Mari M, Reggiori F, Elazar Z. Lipid droplets and their component triglycerides and steryl esters regulate autophagosome biogenesis. EMBO J. 2015;34:2117–31. https://doi.org/10.15252/embj.201490315.CrossRefPubMedPubMedCentral

66.

Zhou W, Xu J, Li H, Xu M, Chen ZJ, Wei W, et al. Neddylation E2 UBE2F promotes the survival of lung cancer cells by activating CRL5 to degrade NOXA via the K11 linkage. Clin Cancer Res. 2017;23:1104–16. https://doi.org/10.1158/1078-0432.CCR-16-1585.CrossRefPubMed

67.

Tan JMM, Wong ESP, Kirkpatrick DS, Pletnikova O, Ko HS, Tay S-P, et al. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet. 2008;17:431–9. https://doi.org/10.1093/hmg/ddm320.CrossRefPubMed

68.

Riley BE, Kaiser SE, Shaler TA, Ng ACY, Hara T, Hipp MS, et al. Ubiquitin accumulation in autophagy-deficient mice is dependent on the Nrf2-mediated stress response pathway: a potential role for protein aggregation in autophagic substrate selection. J Cell Biol. 2010;191:537–52. https://doi.org/10.1083/jcb.201005012.CrossRefPubMedPubMedCentral

69.

Deng Z, Purtell K, Lachance V, Wold MS, Chen S, Yue Z. Autophagy receptors and neurodegenerative diseases. Trends Cell Biol. 2017;27:491–504. https://doi.org/10.1016/j.tcb.2017.01.001.CrossRefPubMed

70.

Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37:1–18. https://doi.org/10.1207/S15327914NC3701_1. CrossRefPubMed

71.

Szumiel I. Autophagy, reactive oxygen species and the fate of mammalian cells. Free Radic Res. 2011;45:253–65. https://doi.org/10.3109/10715762.2010.525233.CrossRefPubMed

72.

Eliopoulos AG, Havaki S, Gorgoulis VG. DNA damage response and autophagy: a meaningful partnership. Front Genet. 2016;7:204. https://doi.org/10.3389/fgene.2016.00204.CrossRefPubMedPubMedCentral

Title: Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA
Authors: Simon Heine
Markus Kleih
Neus Giménez
Kathrin Böpple
German Ott
Dolors Colomer
Walter E. Aulitzky
Heiko van der Kuip
Elisabeth Silkenstedt
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2018
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-018-0657-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT

Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways

The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis

The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer

Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer